Australia: Where Value Beats Cost
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Address: Pharmaxis Ltd20 Rodborough RdFrenchs ForestNSW 2086, AUSTRALIA,Australia
Tel: +61 2 9454 7200
Web: http://www.pharmaxis.com.au/
Pharmaxis is a specialty pharmaceutical company involved in the research, development and commercialisation of new therapies for undertreated respiratory diseases.Our first product, Aridol, is now registered for sale in the United States, Europe, Australia and South East Asia. Aridol is designed to assist in the management of both asthma and chronic obstructive pulmonary disease.
Our second product, Bronchitol, an Australian discovered and developed product which was approved for marketing in Australia in February 2011. In October 2011 Bronchitol received a positive opinion by a European regulatory committee, clearing the way for its marketing in 29 countries in Europe.
We are committed to bringing our therapeutic advances for respiratory and immune diseases to patients throughout the world, and to building an internationally successful pharmaceutical business: one that’s built to last.
Products
Pharmaxis has a strong suite of products in development, primarily focused on treating respiratory diseases. The target disease states are under-treated and many have broad patient bases.
Aridol
Overview
Pharmaxis’ first commercial product, the innovative Aridol lung function test, is designed to assist physicians in the overall assessment of asthma by identifying and measuring airway hyperresponsiveness.
By having patients inhale Aridol via a simple hand-held device, doctors can determine the severity of a patient’s inflammation and prescribe the right amount of medication to bring it under control. The Aridol challenge test potentially prevents inappropriate treatment and may help patients better comply with their therapies.
Aridol is approved for sale in Australia, major European countries, South Korea and the United States. Bronchitol
Overview
Pharmaxis’ key product in development, Bronchitol, is a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions.
Pharmaxis is developing Bronchitol for diseases including bronchiectasis, cystic fibrosis and chronic bronchitis. Bronchitol hydrates the lungs, helps restore normal lung clearance, and allows patients to clear mucus more effectively. Clinical studies have shown Bronchitol to be effective and well tolerated, to improve quality of life and mucus flow in people with cystic fibrosis and bronchiectasis.
Bronchitol is an Australian discovered and developed product which was approved for marketing in Australia in February 2011. In October 2011 Bronchitol received a positive opinion by a European regulatory committee, clearing the way for its marketing in 29 countries in Europe.
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
Senior Partner Dr Sree Haran has also participated in this interview. TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would…
Speaking to the Australian environment, how would you rate the market in terms of companies like Swisse? After traveling the world, the Australian market has shown to be one of…
In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that…
Dr Bernadette Morris-Smith has also participated in this interview TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would you begin…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
“Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008.…
The company underwent some landmark changes under your leadership, changing the balance between different pillars of the business – retail, wholesale product delivery, marketing programs. Would you begin by outlining…
After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and…
Can you start by commenting on the state of diabetes in Australia at present? According to 2011 statistics nearly one million Australians have diabetes and about half of those are…
See our Cookie Privacy Policy Here
